These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 3030773)

  • 41. Dual mechanism of the relaxing effect of nicorandil by stimulation of cyclic GMP formation and by hyperpolarization.
    Kukovetz WR; Holzmann S; Braida C; Pöch G
    J Cardiovasc Pharmacol; 1991 Apr; 17(4):627-33. PubMed ID: 1711631
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Constriction of cat coronary arteries by synthetic thromboxane A2 and its antagonism.
    Smith JB; Yanagisawa A; Zipkin R; Lefer AM
    Prostaglandins; 1987 Jun; 33(6):777-82. PubMed ID: 3671730
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of contractile responses to 5-hydroxytryptamine and sumatriptan in human isolated coronary artery: synergy with the thromboxane A2-receptor agonist, U46619.
    Cocks TM; Kemp BK; Pruneau D; Angus JA
    Br J Pharmacol; 1993 Sep; 110(1):360-8. PubMed ID: 8220898
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Involvement of protein kinase C in reduced relaxant responses to the NO/cyclic GMP pathway in piglet pulmonary arteries contracted by the thromboxane A2-mimetic U46619.
    Pérez-Vizcaíno F; Villamor E; Duarte J; Tamargo J
    Br J Pharmacol; 1997 Aug; 121(7):1323-33. PubMed ID: 9257910
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dilator effect of endothelins in pulmonary circulation: changes associated with chronic hypoxia.
    Eddahibi S; Springall D; Mannan M; Carville C; Chabrier PE; Levame M; Raffestin B; Polak J; Adnot S
    Am J Physiol; 1993 Dec; 265(6 Pt 1):L571-80. PubMed ID: 8279573
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The thromboxane A2/prostaglandin endoperoxide receptor antagonist activity of CV-4151, a thromboxane A2 synthetase inhibitor.
    Imura Y; Terashita Z; Shibouta Y; Nishikawa K
    Eur J Pharmacol; 1988 Mar; 147(3):359-65. PubMed ID: 2967770
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reduction of myocardial damage and polymorphonuclear leukocyte accumulation following coronary artery occlusion and reperfusion by the thromboxane receptor antagonist BM 13.505.
    Griswold DE; Egan JW; Earl CQ; Hillegass LM; Marshall PJ; Smith EF
    Prog Clin Biol Res; 1989; 301():161-5. PubMed ID: 2529547
    [No Abstract]   [Full Text] [Related]  

  • 48. Competitive antagonism at thromboxane receptors in human platelets.
    Armstrong RA; Jones RL; Peesapati V; Will SG; Wilson NH
    Br J Pharmacol; 1985 Mar; 84(3):595-607. PubMed ID: 2580580
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Heterogeneity of vascular smooth muscle responsiveness to lipid vasoactive mediators.
    Stahl GL; Lefer AM
    Blood Vessels; 1987; 24(1-2):24-30. PubMed ID: 3567363
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characteristics of canine coronary resistance arteries: importance of endothelium.
    Myers PR; Banitt PF; Guerra R; Harrison DG
    Am J Physiol; 1989 Aug; 257(2 Pt 2):H603-10. PubMed ID: 2788367
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Heterogeneity of thromboxane A2 (TP-) receptors: evidence from antagonist but not agonist potency measurements.
    Tymkewycz PM; Jones RL; Wilson NH; Marr CG
    Br J Pharmacol; 1991 Mar; 102(3):607-14. PubMed ID: 1364826
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of the new thromboxane A2 antagonist vapiprost on isolated canine blood vessels.
    Matsuzaki T; Noguchi K; Nakasone J; Uezu K; Higuchi M; Sakanashi M
    Arzneimittelforschung; 1992 Nov; 42(11):1318-22. PubMed ID: 1492844
    [TBL] [Abstract][Full Text] [Related]  

  • 53. BM 13.177, a selective blocker of platelet and vessel wall thromboxane receptors, is active in man.
    Gresele P; Deckmyn H; Arnout J; Lemmens J; Janssens W; Vermylen J
    Lancet; 1984 May; 1(8384):991-4. PubMed ID: 6143969
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Thimerosal blocks stimulated but not basal release of endothelium-derived relaxing factor (EDRF) in dog isolated coronary artery.
    Crack P; Cocks T
    Br J Pharmacol; 1992 Oct; 107(2):566-72. PubMed ID: 1384915
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mechanism of renal vasoconstriction with thromboxane mimetic: engagement of tubuloglomerular feedback.
    Welch WJ; Wilcox CS; Folger WH
    Adv Prostaglandin Thromboxane Leukot Res; 1991; 21B():693-6. PubMed ID: 1825399
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Differences in activities of thromboxane A2 receptor antagonists in smooth muscle cells.
    Miki I; Kase H; Ishii A
    Eur J Pharmacol; 1992 Oct; 227(2):199-204. PubMed ID: 1426029
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Role of endothelium-derived prostanoid in angiotensin-induced vasoconstriction.
    Lin L; Nasjletti A
    Hypertension; 1991 Aug; 18(2):158-64. PubMed ID: 1885223
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Selective impairment of endothelium-dependent relaxations by prostaglandin endoperoxide.
    Tesfamariam B
    J Hypertens; 1994 Jan; 12(1):41-7. PubMed ID: 8157943
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term estradiol replacement decreases contractility of guinea pig coronary arteries to the thromboxane mimetic U46619.
    Thompson LP; Weiner CP
    Circulation; 1997 Feb; 95(3):709-14. PubMed ID: 9024161
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of U46619 on contractions to 5-HT, sumatriptan and methysergide in canine coronary artery and saphenous vein in vitro.
    Kemp BK; Cocks TM
    Br J Pharmacol; 1995 Oct; 116(4):2183-90. PubMed ID: 8564247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.